Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Sep;76(5):1569-1571.
doi: 10.1007/s13304-024-01956-7. Epub 2024 Aug 16.

REDISCOVER the change in surgical management of pancreatic cancer from anatomy to biology

Marco Ventin  1 , Cristina R Ferrone  2
Affiliations
Editorial

REDISCOVER the change in surgical management of pancreatic cancer from anatomy to biology

Marco Ventin et al. Updates Surg. 2024 Sep.
No abstract available

Keywords: Biologic resectability; Borderline resectable; Locally advanced; PDAC; Pancreatic ductal adenocarcinoma; Surgical management.

PubMed Disclaimer

References

    1. Boggi U, Kauffmann E, Napoli N et al (2024) REDISCOVER international guidelines on the perioperative care of surgical patients with borderline-resectable and locally advanced pancreatic cancer. Ann Surg 280(1):56–65. https://doi.org/10.1097/SLA.0000000000006248 - DOI - PubMed
    1. Boggi U, Kauffmann EF, Napoli N et al (2024) REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Updates Surg. https://doi.org/10.1007/s13304-024-01860-0 - DOI - PubMed - PMC
    1. Murphy JE, Wo JY, Ryan DP et al (2018) Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol 4(7):963–969. https://doi.org/10.1001/jamaoncol.2018.0329 - DOI - PubMed - PMC
    1. Katz MHG, Shi Q, Meyers J et al (2022) Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial. JAMA Oncol 8(9):1263–1270. https://doi.org/10.1001/jamaoncol.2022.2319 - DOI - PubMed - PMC
    1. Ferrone CR, Marchegiani G, Hong TS et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261(1):12–17. https://doi.org/10.1097/SLA.0000000000000867 - DOI - PubMed

Publication types

LinkOut - more resources